Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial-Reference-Cited by-同舟云学术

Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial

Published:2022-08 Issue:8 Volume:23 Page:1031-1043
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Tam Constantine S,Brown Jennifer R,Kahl Brad S,Ghia Paolo,Giannopoulos Krzysztof,Jurczak Wojciech,Šimkovič Martin,Shadman Mazyar,Österborg Anders,Laurenti Luca,Walker Patricia,Opat Stephen,Chan Henry,Ciepluch Hanna,Greil Richard,Tani Monica,Trněný Marek,Brander Danielle M,Flinn Ian W,Grosicki Sebastian,Verner Emma,Tedeschi Alessandra,Li Jianyong,Tian Tian,Zhou Lei,Marimpietri Carol,Paik Jason C,Cohen Aileen,Huang Jane,Robak Tadeusz,Hillmen Peter

Publisher

Elsevier BV

Subject

Oncology

Reference31 articles.

1. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL;Hallek;Blood,2018

2. Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia;Shanafelt;N Engl J Med,2019

3. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL;Woyach;N Engl J Med,2018

4. Final analysis from RESONATE: up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma;Munir;Am J Hematol,2019

5. Acalabrutinib (ACP-196): a covalent bruton tyrosine kinase inhibitor with a differentiated selectivity and in vivo potency profile;Barf;J Pharmacol Exp Ther,2017

Cited by 123 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacological management of chronic lymphocytic leukemia: current and emerging therapies;Expert Opinion on Pharmacotherapy;2024-09-08

2. Utilizing risk factors to guide treatment decisions in chronic lymphocytic leukemia;Expert Review of Anticancer Therapy;2024-09-02

3. Real-World Treatment Patterns and Outcomes by Line of Therapy and Race in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated in the United States: Results From the Final Analysis of the Prospective, Observational, informCLL Registry;Clinical Lymphoma Myeloma and Leukemia;2024-09

4. Safety profile of first-line targeted therapies in elderly and/or comorbid chronic lymphocytic leukaemia patients (unfit subpopulation). A systematic review and network meta-analysis;Critical Reviews in Oncology/Hematology;2024-09

5. Severe infections in patients with chronic lymphocytic leukemia included in trials investigating BTK and BCL2 inhibitors;Critical Reviews in Oncology/Hematology;2024-09